Active Ingredient History
Mirabegron (trade name Myrbetriq in the US and Betmiga in Europe) is a drug for the treatment of overactive bladder (OAB). It was developed by Astellas Pharma and was approved in the United States in July 2012. Originally developed as a treatment for diabetes, the development of mirabegron was later refocused to OAB. Mirabegron is an orally bioavailable agonist of the human beta-3 adrenergic receptor (ADRB3), with muscle relaxing, neuroprotective and potential antineoplastic activities. Upon oral administration, mirabegron binds to and activates ADRB3, which leads to smooth muscle relaxation. Mirabegron also restores sympathetic stimulation in mesenchymal stem cell (MSC) niches, inhibits JAK2-mutated hematopoietic stem cell (HSC) expansion and blocks the progression of myeloproliferative neoplasms (MPNs). Lack of sympathetic stimulation of the MSC and HSC niche is associated with the development of MPNs. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Adipose Tissue, Brown (Phase 2)
Autonomic Dysreflexia (Phase 2)
Autonomic Nervous System Diseases (Phase 2)
Baroreflex (Phase 2)
Biological Availability (Phase 1)
Blood Pressure (Phase 2)
Cardiovascular Diseases (Phase 1)
Cerebrovascular Circulation (Phase 2)
Cognition (Phase 2)
Cognition Disorders (Phase 4)
Cystitis, Interstitial (Phase 4)
Drug Interactions (Phase 1)
Drugs, Investigational (Phase 2)
Energy Transfer (Phase 1/Phase 2)
Erectile Dysfunction (Phase 1/Phase 2)
Esophageal Achalasia (Early Phase 1)
Flank Pain (Phase 2)
Healthy Volunteers (Phase 4)
Heart Failure (Phase 2/Phase 3)
Hypertension, Pulmonary (Phase 2)
Hypertrophy, Left Ventricular (Phase 2)
Hypotension (Phase 2)
Intraocular Pressure (Phase 1)
Kidney Failure, Chronic (Phase 1)
Liver Diseases (Phase 1)
Lower Urinary Tract Symptoms (Phase 2)
Lung Diseases (Phase 2)
Metabolic Syndrome (Early Phase 1)
Metabolism (Phase 1)
Multiple Sclerosis (Phase 4)
Myeloproliferative Disorders (Phase 2)
Nephrolithiasis (Phase 4)
Obesity (Phase 4)
Pain (Phase 2)
Parkinson Disease (Phase 4)
Pharmacokinetics (Phase 4)
Pharmacology (Phase 4)
Polycystic Ovary Syndrome (Phase 1)
Polycythemia Vera (Phase 2)
Prediabetic State (Phase 4)
Primary Myelofibrosis (Phase 2)
Prostatic Hyperplasia (Phase 4)
Signs and Symptoms (Phase 2)
Sjogren's Syndrome (Phase 4)
Spinal Cord Injuries (Phase 2)
Stents (Phase 3)
Thermogenesis (Phase 1/Phase 2)
Thrombocythemia, Essential (Phase 2)
Ureteral Diseases (Phase 3)
Ureteral Obstruction (Phase 2)
Urinary Bladder (Phase 3)
Urinary Bladder Diseases (Phase 4)
Urinary Bladder Neck Obstruction (Phase 2)
Urinary Bladder, Neurogenic (Phase 2/Phase 3)
Urinary Incontinence (Phase 3)
Urinary Incontinence, Urge (Phase 4)
Urination Disorders (Phase 4)
Urological Manifestations (Phase 2)
Urologic Diseases (Phase 3)
Vagus Nerve (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
